HistoSonics’ Kidney Cancer Trial Using Non-Invasive Histotripsy Gets FDA Nod

On Monday, medical device company HistoSonics announced that the US Food and Drug Administration (FDA) has approved the company’s sponsored #HOPE4KIDNEY investigational device exemption (IDE) trial that uses a new sonic beam therapy called histotripsy. The clinical trial will evaluate the safety and technical success of the company’s Edison System in non-invasively targeting and destroying primary renal tumors without the need for incisions or needles.